Idiopathic pulmonary fibrosis (IPF) is a fatal disease that's all the more difficult for patients because of a lack of awareness and investment in supporting people with the condition.
Leela Barham takes a look behind the schemes for patient access in England and puts the case for a review to bring them up to date, in the light of changes since they began in 2009.
Patient support programmes that extend beyond the prescription are increasingly important, with neurologists among the most experienced in such services.
New initiatives from the country's regulator aim to smooth the registration of trials and ensure prospective participants fully understand what will be involved through mandatory AV recording o
People wanting to establish rare disease support groups face lack of understanding and awareness from the medical profession, challenges finding others with the same condition, often little fun
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.